Sequence Holdings Raises $75M Series A Funding

Starfighters Space (NYSE AMERICAN: FJET)

Starfighters Space is an opportunity to participate in high-demand commercial space activities. -Located at NASA’s Kennedy Space Center in Florida alongside SpaceX, Blue Origin and Terran Orbital -F-104 acts as first stage carrying payloads to 45,000 feet for air launch to space -Hypersonic testing as part of air launch partner development program -Fleet of seven F-104 fighter jets - the only commercial fleet in the world - will be capable of launching satellites through Starfighters SILA program -Market ready with minimal R&D time given proven propulsion technology -We aim to be one of the most cost-effective launch providers* -Current customers include Lockheed Martin, US Air Force, Northrop Grumman, Blue Origin, Meggitt, and Avio *In process of acquiring launch license with FAA.

General Compute

General Compute is building the world's fastest AI cloud. AI agents, coding tools, and voice assistants all share one constraint: token generation speed. The infrastructure serving them today was built for training, not inference. We're fixing that. General Compute is the first ASIC-first AI neocloud, purpose-built for high-speed inference. Our platform delivers 5-7x faster token generation than GPU-based clouds, serving the latency-sensitive workloads that are growing fastest: coding agents, voice AI, and autonomous systems.

Kubera Health

Kubera’s mission is to power a payment ecosystem where contracts are honored, care is rewarded, and waste is eliminated. We deliver contract and payment intelligence that unifies policies, terms, and claims data into one trusted platform — helping healthcare organizations and their partners build fairer contracts, ensure payments flow as intended, and align incentives across the care ecosystem. As healthcare shifts toward new reimbursement models and risk-sharing arrangements, Kubera is building the payment-intelligence backbone that enables multiple parties to adapt faster, protect margins, and dedicate more resources to patient care.

Psilera

Psilera is a biotechnology company founded by scientists dedicated to finding better therapeutics for neurological conditions like dementia, addiction, and mental health disorders. Since 2019, Psilera has been focused on early-stage drug discovery & development with a dynamic team of experts in synthetic chemistry, pharmacology, clinical development, and business development.

Abstract

Abstract is a venture capital firm based in San Francisco with $1.5 billion in assets under management. We are sector-agnostic, focused on seed and early stage founders. Our reputation among founders is built on fierce loyalty, unparalleled connections, and a relentless drive to help them win.